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Cell therapy targets the treatment of some of the most widespread and difficult diseases, many of them 
representing unmet medical needs.  To date, there are several promising cell therapy treatments in Phase III of 
clinical trials, which once proven effective for the treatment of their target indication, will not only be a significant 
medical breakthrough but also result in very high global demand.  If the manufacturing costs of these therapies 
are too expensive, many patients will not have access to them. Therefore, the commercialization of many, if not 
all, cell therapy processes will require novel approaches to manufacturing which are cost effective, robust, and 
efficient.   
 
Continuous bioprocessing streamlines manufacturing resource requirements such as labor, equipment, and 
consumables in a cost-effective manner while increasing throughput and productivity. An appropriate cell 
therapy platform should be scalable, robust, and maximize final product yield while keeping both costs low and 
the final product quality at a high standard.  While the focus off allogeneic cell therapies is to “scale up” 
production for the treatment of large numbers of individuals per lot and autologous cell therapies focus on “scale 
out” production for maximized number of individualized patient cell lot production, there are overlapping best 
practices and technologies used in both types of cell therapy processes, as well as in current continuous protein 
biomanufacturing, utilized for scalable, continuous, end-to-end processing in a completely closed and 
disposable platforms.   
 
This presentation will highlight current cell therapy end-to-end platform solutions which are scalable, robust, 
automated, and maximize final product yield while keeping both costs low and the final product quality at a high 
standard.  We will also identify common bottlenecks and challenges in cell therapy manufacturing, including 
facility designs, and explore potential solutions utilizing modified continuous mAb/protein/viral bioprocessing 
methods and technologies for the optimization of cell based therapy products.  
 
 
